Treated for newly diagnosed Hodgkin's lymphoma with brentuximab vedotin: one case report and literature review
2017
Objective
To deepen the understanding of curative effect and adverse drug reaction of brentuximab vedotin in the treatment of Hodgkin's lymphoma.
Methods
One case of newly diagnosed Hodgkin's lymphoma who treated with brentuximab vedotin was collected.The clinical features, laboratory examination, treatment procedure, prognosis were analyzed, and the relevant literature was reviewed.
Results
The patient was twenty years old, female, found the right neck masses for five days, diagnosed with Hodgkin's lymphoma, mixed cell type, stage IV group B. Chose the chemotherapy regimen BV+ GABVD for 4 courses, the PET-CT indicated CR, then used GABVD 4 courses, now in the stage of clinical observation and followed up.
Conclusion
BV is a kind of antibody-drug conjugate which targeted on CD30 protein.The FDA approved for the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma.The common adverse reactions are granulocyte, peripheral neuropathy, fatigue, nausea and vomiting.BV can significantly improve the prognosis of CD30 positive Hodgkin's lymphoma, but need to pay attention to the prevention of adverse reactions.
Key words:
Lymphoma; Antigens, CD30; Brentuximab vedotin; Prognosis
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI